Radiopharmaceuticals in Nuclear Medicine Market will Witness Huge Growth till 2027 & Covid-19 Analysis | Life Molecular Imaging ,Jubilant Life Sciences Ltd.,DuChemBio, Inc.

 

Radiopharmaceuticals are radioactive compounds with a bonded radionuclide in their structure that are used to guide the radionuclide to a target for treatment or imaging. Nuclear medicine is a medical specialty that makes use of radiopharmaceuticals, which have proven to be a very effective ally in numerous diagnostics and treatments, particularly for cancer. By 2027, the Radiopharmaceuticals In Nuclear Medicine market size is expected to grow at a CAGR of 6.47% from the 2020 market size of USD 3.99 Billion. 

Nuclear Medicine Market Directions 

Drivers: Increasing incidence and prevalence of target conditions 

A major element driving market expansion is the increased incidence and prevalence of cancer and cardiovascular disease (CVD). Early detection and treatment can prevent the majority of instances, and nuclear medicine can help. Cancer was the biggest cause of death in 2020, according to the World Health Organization, with approximately 10 million deaths. By 2025, it is estimated that 19.3 million new cancer cases will be recorded annually over the world. According to the World Health Organization, 17.9 million people died from cardiovascular disease (CVD) in 2019, accounting for 32% of all deaths. By 2030, this number will have risen to 23.3 million. Given the importance of nuclear medicine in disease diagnosis and treatment. The increased prevalence of various disorders is likely to fuel the expansion of the Radiopharmaceuticals in Nuclear Medicine Market during the forecast period, as nuclear medicine plays a key role in disease diagnosis and treatment. 

 Restrains Short half-life of radiopharmaceuticals 

The half-life of the radioisotope and the concentration of the radionuclide are the most important factors in determining when a radiopharmaceutical will expire. F-18's radioactivity in PET scans, for example, declines if not utilized within 110 minutes, but C-11's radioactivity reduces within 20 minutes. Tc-99m radioactivity decreases after six hours in SPECT diagnosis, while I-123 and In-111 isotopes should be used within 13 and 67 hours, respectively. Radiation and chemical breakdown occurs when radioisotopes are not used within the designated shelf life, reducing radiochemical purity to an unacceptable level, which can be lethal during diagnostic and therapy. 

 COVID-19 Analysis

 Coronavirus disease 2019 (COVID19) is an acute respiratory infectious disease caused by the coronavirus 2 (SARSCoV2) of severe acute respiratory syndrome. COVID-19 was hardly unknown before the outbreak in Wuhan, China, in December 2019. In just a few weeks, it went from a regional catastrophe to a global epidemic. COVID-19 was declared a pandemic by the World Health Organization (WHO) on March 11, 2020. The COVID-19 pandemic has resulted in significant modifications in radiology department clinical operations around the world. Academic medical centers and universities were rushed to shut down scientific research operations in concert with clinical readiness activities in order to increase social separation and reduce risk.